Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	0.4860 kr	+6.23%	681,022
11/06/26	0.4575 kr	+3.62%	592,487
10/06/26	0.4415 kr	-3.92%	1,521,143
09/06/26	0.4595 kr	-0.11%	4,486,313
08/06/26	0.4600 kr	+3.14%	740,111

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 20:00:00 12/06/2026 +04			5-day change	1st Jan Change
0.4860 ^SEK	+6.23%		+8.97%	-41.38%

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW

Market Cap	75.31M 8.01M 6.92M 6.38M 5.97M 11.19M 762M 11.36M 29.36M 371M 30.08M 29.44M 1.28B	P/E Ratio 2026 *	-1.52x	P/E Ratio 2027 *	-0.99x
Enterprise Value	72.31M 7.69M 6.65M 6.12M 5.73M 10.74M 731M 10.91M 28.19M 356M 28.88M 28.26M 1.23B	EV / Sales 2026 *	2.31x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE
05-13	Alzinova reports narrowed operating loss - CEO: we see rapidly growing commercial interest in diagnostics	FW
05-11	Alzinova article on Alzheimer's vaccine published in scientific journal	FW
05-11	Alzinova AB Announces Clinical Results with Alz-101 to Be Published in Scientific Journal	CI
05-05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT
04/10/25	Alzinova AB Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer's Disease	CI

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ
05-26	Bulletin from the Annual General Meeting of Alzinova AB (publ)	AQ
05-25	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today	AQ

1 day	+6.23%
1 week	+8.97%
Current month	+12.89%
1 month	+15.58%
3 months	-47.00%
6 months	-70.37%
Current year	-41.38%

1 week	0.44	0.58
1 month	0.41	0.58
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.18
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+6.23%	+8.97%	-72.70%	-83.64%	8.01M
LONZA GROUP AG	-0.35%	+0.97%	-13.80%	-13.83%	43.03B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+279.08%	+509.39%	32.71B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+15.66%	-14.70%	30.29B
BEONE MEDICINES AG	+1.62%	-2.08%	-1.91%	+27.08%	29.4B
CELLTRION, INC.	+4.09%	+0.93%	+12.97%	+20.66%	25.08B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.54B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+56.69%	+114.08%	13.35B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.23%	+6.41%	12.97B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.89%	+79.51%	12.11B
Average	+1.33%	+2.20%	+43.12%	+71.66%	21.25B
Weighted average by Cap.	+1.05%	+1.48%	+57.29%	+98.05%

	2026 *	2027 *
Net sales	31.35M 3.34M 2.88M 2.66M 2.49M 4.66M 317M 4.73M 12.22M 154M 12.52M 12.25M 534M	-
Net income	-3.2M -341K -294K -271K -254K -475K -32.37M -483K -1.25M -15.75M -1.28M -1.25M -54.55M	-50.35M -5.36M -4.63M -4.26M -3.99M -7.48M -509M -7.6M -19.63M -248M -20.11M -19.68M -858M
Net Debt	-3M -319K -276K -254K -238K -446K -30.34M -453K -1.17M -14.77M -1.2M -1.17M -51.14M	-7M -745K -643K -593K -555K -1.04M -70.8M -1.06M -2.73M -34.46M -2.8M -2.74M -119M